Company:  CYTRX CORP (CYTR)
Form Type:  8-K
Filing Date:  4/23/2012 
CIK:  0000799698 
Address:  11726 SAN VICENTE BOULEVARD
SUITE 650
 
City, State, Zip:  LOS ANGELES, California 90049 
Telephone:  310-826-5648 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$3.18  
Change: 
0.035 (1.11%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$176.69M
Description of Business
References in this Annual Report to the �company,� �we,� �us� or �our� refer to CytRx Corporation, unless otherwise indicated. COMPANY OVERVIEW We are a biopharmaceutical research and development company specializing in oncology. We currently are focused on the clinical development of aldoxorubicin (formerly known as INNO-206), our modified version of the widely-used chemotherapeutic agent, doxorubicin. We recently reported top-line efficacy results (median progression-free survival, progression-free survival at six months, overall response rates and hazard ratios) of our Phase 2b clinical trial with aldoxorubicin as a treatment for soft tissue sarcoma, or STS. Hazard ratios - the likelihood that the study endpoint (in this case tumor progression) will be reached during a given period - are an important measure of the reliability and uniformity of the absolute data for progression-free survival, or PFS.
Register for EDGAR Pro and access this filing in:     
  FORM 8-K
    SECTION 8 OTHER EVENTS
      ITEM 8.01. Other Events.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01. Financial Statements and Exhibits.
    SIGNATURES
    INDEX TO EXHIBITS
  EXHIBIT 99.1
BROKERAGE PARTNERS